Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT05177770 is registered in ClinicalTrials.gov with Coherus Oncology, Inc. as lead sponsor.

NCT NCT05177770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05177770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of SRF617 in Combination With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Coherus Oncology, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 17, 2022
Completion date
April 5, 2023
Enrollment
16 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer, prostate cancer